<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335544">
  <stage>Registered</stage>
  <submitdate>26/07/2017</submitdate>
  <approvaldate>24/10/2017</approvaldate>
  <actrnumber>ACTRN12617001498381</actrnumber>
  <trial_identification>
    <studytitle> Use of antibiotic prophylaxis in the prevention of postoperative infection of third impacted mandibular molars</studytitle>
    <scientifictitle>Antibiotic Prophylaxis in the prevention of infectious complications in mandibular impacted third molars extraction: A randomized clinical trial</scientifictitle>
    <utrn>U1111-1115-1535 </utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Postoperative surgical wound infection in helathy people</healthcondition>
    <healthcondition>'Impacted third molars</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>2 gr. Amoxicillin one hour before the surgery . Oral tablet</interventions>
    <comparator>Placebo: Microcellulose</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Alveolar osteitis: postoperative pain inside and around the extraction site, which increases in severity at any time between the first and third day after the extraction, accompanied by a partial or total disintegrated blood clot within the alveolar socket with or without halitosis. The assessment  is performed by clinical examination.</outcome>
      <timepoint>48 hrs
7 days
30 days
</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Surgical Site infection. The presence of surgical site infection was considered when the patient present at least one of the following characteristics:
A. Purulent drainage by surgical wound or abscess. 
B. Isolation of pathogenic microorganisms in liquid or tissue culture at the surgical site. 
C. Spontaneous dehiscence at the incision site in patients who exhibit at least one of the following signs of symptoms: 1) fever (&gt; 38 ° C) 2)  spontaneous pain on palpation 3 localized swelling, facial erythema or local heat.
E. Severe pain after 7th day accompanied by intraoral inflammation (moderate or severe) and/or intraoral erythema (moderate or severe) for no other justifiable reason which improves with antibiotic treatment

</outcome>
      <timepoint>48 hrs
7 days
30 days
</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Rescue Medication: An additional dose of analgesic used to control persistent pain that not replace or delay the next dose of analgesic indicated in the first instance. 
Lysine clonexinate (tablets) 125 mg  when pain is superior than 4 VAS

 Rescue medication will assessed as dichotomous outcome</outcome>
      <timepoint>Rescue analgesia were indicated by patients reporting pain greater than 4 on the visual analog scale. 24 hours and 48 hours after surgery
</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse reactions related to the use of amoxicillin: 
Allergic reaction: Presence of urticaria and/or angiodema
Anaphylaxis: Throat or tongue swelling and / or Respiratory symptoms
Gastrointestinal Reaction: Nausea, Vomiting, Abdominal Pain, Diarrhea
The assessment is performed by clinical examinations
</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy patients between 15 to 35 years old: Clinically and radiographically  presence at least of one impacted mandibular third molar, 
</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Pregnancy.
Allergy to penicillin and its derivatives.
Allergy to nonsteroidal anti-inflammatory drugs.
Patients with gastric ulcer.
Patients who have undergone any type of antibiotic treatment at least 30 days before surgery.
Patients with pericoronaritis episode up to 7 days before the intervention.
Patients with psychiatric illness.
Immunocompromised
Patients with addiction to narcotic drugs or illicit substances</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation involved contacting the holder of the allocation schedule who was "off-site.
</concealment>
    <sequence>Permuted blocks
</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Statistical test: chi-square.

The results will be expressed as risk estimators: Absolute risk reduction. - Relative risk. Number needed to treat.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>2/05/2016</actualstartdate>
    <anticipatedenddate>6/11/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <currentsamplesize>116</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>8/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Facultad de Odontología. Universidad de Chile</primarysponsorname>
    <primarysponsoraddress>Sergio Livingstone P 943. Independencia, postcode 8380492 Santiago</primarysponsoraddress>
    <primarysponsorcountry>Chile</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Facultad de Odontología Universidad de Chile</fundingname>
      <fundingaddress>Sergio Livingstone P 943. Independencia, postcode 8380492
Santiago</fundingaddress>
      <fundingcountry>Chile</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Hospital Clínico San Borja Arriaran</sponsorname>
      <sponsoraddress>Santa Rosa 1234, Santiago Centro
postcode 8360160</sponsoraddress>
      <sponsorcountry>Chile</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Facultad de Odontología. Universidad Complutense de Madrid</sponsorname>
      <sponsoraddress>Pza. Ramón y Cajal, s/n, 28040 Madrid</sponsoraddress>
      <sponsorcountry>Spain</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Third molar surgery is the most frequent procedure in oral and maxillofacial surgery. Surgical wound infection is the most prevalent complication.
Determine if the use of 2 gr. of Amoxicillin as AP reduces the proportion of postoperative infectious complications in the impacted third molar extraction compared to placebo.
To determine the proportion of postoperative infectious complications of the experimental group (2 gr Amoxicillin) and control group (placebo) derived from the exodoncia of impacted mandibular third molars.
To compare the proportion of postoperative infectious complications of the experimental group versus the control group.
To compare the proportion of rescue medication requirement associated with postoperative pain between the experimental group versus the control group.
Describe any adverse reactions resulting from the use of 2 gr. Amoxicillin as AP.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite etico cientifico del Servicio de Salud Metropolitano Central</ethicname>
      <ethicaddress>Victoria Subercaseaux 381. Postcode 8320143.
Santiago</ethicaddress>
      <ethicapprovaldate>26/04/2016</ethicapprovaldate>
      <hrec>27/16</hrec>
      <ethicsubmitdate>14/03/2016</ethicsubmitdate>
      <ethiccountry>Chile</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Nicolas Yanine Montaner</name>
      <address>Facultad de Odontología Universidad de Chile
Sergio Livingstone P 943, Independencia 8380492
Santiago</address>
      <phone>+56990653100</phone>
      <fax />
      <email>nyanine@u.uchile.cl</email>
      <country>Chile</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Julio Villanueva Maffei</name>
      <address>Facultad de Odontología Universidad de Chile
Sergio Livingstone P 943, Independencia 8380492
Santiago</address>
      <phone>+56998273373</phone>
      <fax />
      <email>javm@uchile.cl</email>
      <country>Chile</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicolas Yanine Montaner</name>
      <address>Sergio Livingstone P 943, Independencia 8380492
Santiago</address>
      <phone>+56990653100</phone>
      <fax />
      <email />
      <country>Chile</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicolas Yanine Montaner</name>
      <address>Facultad de Odontologia. Universidad de Chile
Sergio Livingstone P 943, Independencia 8380492
Santiago</address>
      <phone>+56990653100</phone>
      <fax />
      <email>nyanine@u.uchile.cl</email>
      <country>Chile</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>